1. Home
  2. FGBI vs CRDL Comparison

FGBI vs CRDL Comparison

Compare FGBI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$10.81

Market Cap

151.6M

Sector

Finance

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
CRDL
Founded
1934
2017
Country
United States
Canada
Employees
346
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.6M
132.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FGBI
CRDL
Price
$10.81
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
22.5K
334.6K
Earning Date
04-27-2026
05-14-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$567.70
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.31
$0.88
52 Week High
$11.02
$1.71

Technical Indicators

Market Signals
Indicator
FGBI
CRDL
Relative Strength Index (RSI) 63.31 34.33
Support Level $7.98 $0.93
Resistance Level N/A $1.09
Average True Range (ATR) 0.42 0.06
MACD 0.07 -0.00
Stochastic Oscillator 75.66 16.33

Price Performance

Historical Comparison
FGBI
CRDL

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: